All In Biotech

Drug Trial Radar · NCT04032067

Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

Last checked: Nov 19, 2026Latest source record: Aug 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 423 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

423

Actual

Start

Oct 30, 2019

Primary completion

Mar 17, 2022

Study completion Mar 17, 2022

Sponsor

Lead sponsor
GemVax & KaelIndustry
Sponsor type
Industry
First posted
Jul 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered as a treatment for Benign prostate hyperplasia(BPH). The investigational drug, GV1001, was first developed as a cancer vaccine for use as active immunotherapy of cancer forms expressing telomerase (eg, pancreatic cancer, prostate cancer, etc.). Subsequently, it was found that GV1001 showed efficacy in alleviating BPH symptoms during in vivo studies by reducing the size of the prostate gland. Based on the result, the effectiveness of GV1001 as a treatment for BPH has been assessed in experimental animals that are designed to develop BPH. It is considered that GV1001 acts to alleviate BPH and the results obtained from previous phase II study indicate that GV1001 may provide potential beneficial effects in BPH patients. So this study is to verify the efficacy and safety of GV1001 on BPH population, large-scale clinical study than phase II.

Conditions

  • Benign Prostatic Hyperplasia (BPH)

Interventions

  • GV1001 placeboDrug

    0.9 % Normal Saline

  • Proscar placeboDrug

    PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in International Prostate Symptom Score(IPSS)Time frame: Week 24

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Hallym University Medical Center

    Anyang, South Korea

  • Inje University Busan Paik Hospital

    Busan, South Korea

  • Samsung Changwon Medical Center

    Changwon, South Korea

  • Soonchunhyang University Hospital

    Cheonan, South Korea

  • Daegu Catholic University Medical Center

    Daegu, South Korea

  • Keimyung University Dongsan Medical Center

    Daegu, South Korea

  • Kyungpook National University Chilgok Hospital

    Daegu, South Korea

  • Yeungnam University Medical Center

    Daegu, South Korea

  • Dongguk University Ilsan Hospital

    Ilsan, South Korea

  • Jeonbuk National University Hospital

    Jeonju, South Korea

  • Chungbuk National University Hospital

    Jungbuk, South Korea

  • Chonnam National University Hospital

    Jungnam, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Chung-ang University Hospital

    Seoul, South Korea

  • Eulji General Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • The Catholic University of Korea, Seoul ST. Mary's Hospital

    Seoul, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, South Korea

  • Hanyang University Guri Hospital

    Guri-si, Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Dongguk University Gyeongju Hospital

    Gyeongju, Gyeongsangbuk-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.